Biogen builds case for its Alzheimer's drug, but skeptics say more data needed
Biogen Inc. laid out more data Thursday on its experimental Alzheimer's drug, raising no major safety alarms but also offering little compelling evidence that the drug, once declared a failure, actually works. Experts had been watching closely for any statistical abnormalities or excess safety issues ...
Japanese manufacturers are growing frustrated yet again over another delay in Britain's withdrawal from the European Union, as the prolonged confusion is raising concerns over disruptions to their businesses and supply chains. Britain is expected to postpone their withdrawal from the union, previously slated for ...
Biogen and Eisai revive plans for Alzheimer's drug aducanumab, but prospects still shaky
Biogen Inc. revived plans on Tuesday to seek U.S. approval for the Alzheimer's treatment aducanumab and said data from more patients in two discontinued studies showed the drug reduced the decline of patients. The drugmaker's shares soared 27 percent in New York trading, recouping almost ...
Pill-popping is a business worth watching for Japan's drugmakers
To eke out growth in one of the developed world's most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers. Medication adherence is seen as an impediment to health as well as sales in Japan, and companies including Otsuka Pharmaceutical ...
Just days after Biogen Inc. revealed promising early data from an experimental Alzheimer's treatment, new research from the Mayo Clinic may revive a long-running debate over whether the drug industry is focusing on the right target in developing therapies to treat the disease. The study, ...
